8-K

TENET HEALTHCARE CORP (THC)

8-K 2024-05-23 For: 2024-05-22
View Original
Added on April 07, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_______________

FORM 8-K

_______________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report: May 22, 2024

(Date of earliest event reported)

_______________

TENET HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada 1-7293 95-2557091
(State of Incorporation) (Commission File Number) (IRS Employer<br>Identification Number)

14201 Dallas Parkway

Dallas, TX 75254

(Address of principal executive offices, including zip code)

(469) 893-2200

(Registrant’s telephone number, including area code)

_______________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading<br>Symbol(s) Name of each exchange <br>on which registered
Common stock, $0.05 par value THC NYSE
6.875% Senior Notes due 2031 THC31 NYSE

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     ☐

Item 5.07. Submission of Matters to a Vote of Security Holders.

The 2024 Annual Meeting of Shareholders (the “Annual Meeting”) of Tenet Healthcare Corporation (the “Company”) was held on May 22, 2024. Below are the final voting results from the meeting.

1.    The Company’s shareholders elected the following directors to serve on the Company’s Board of Directors, each to serve until the next annual meeting of shareholders or until his or her successor is duly elected or qualified, whichever is later, or until the director’s earlier resignation or removal:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
Saumya Sutaria 78,408,106 2,952,599 32,017 7,127,343
J. Robert Kerrey 79,073,669 2,287,690 31,364 7,127,343
Vineeta Agarwala 81,165,083 196,130 31,509 7,127,343
James L. Bierman 80,681,369 679,552 31,802 7,127,343
Roy Blunt 80,901,184 459,196 32,343 7,127,343
Richard W. Fisher 80,876,576 483,410 32,737 7,127,343
Meghan M. FitzGerald 79,983,800 1,373,328 35,595 7,127,343
Cecil D. Haney 80,749,317 612,662 30,744 7,127,343
Christopher S. Lynch 80,998,870 361,100 32,753 7,127,343
Richard J. Mark 80,881,920 478,921 31,882 7,127,343
Tammy Romo 80,830,618 530,853 31,252 7,127,343
Stephen H. Rusckowski 81,110,163 250,471 32,089 7,127,343
Nadja Y. West 80,637,096 723,225 32,401 7,127,343

2.    The Company’s shareholders approved, on an advisory basis, the Company’s executive compensation:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
78,324,154 2,920,906 147,662 7,127,343

3.    The Company’s shareholders approved the ratification of the selection of Deloitte & Touche LLP as the Company’s independent registered public accountants for the year ending December 31, 2024:

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
87,988,280 496,790 34,996

4.    The shareholder proposal requesting a report on risk mitigation regarding state restrictions for emergency abortions did not pass.

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
4,059,525 75,912,077 1,421,120 7,127,343

5.    The shareholder proposal requesting a report on plans to integrate ESG metrics into executive compensation did not pass.

FOR AGAINST ABSTAIN BROKER<br><br>NON-VOTES
4,328,821 76,596,569 467,332 7,127,343

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENET HEALTHCARE CORPORATION
Date: May 23, 2023 By: /s/ THOMAS ARNST
Name: Thomas Arnst
Title: Executive Vice President, Chief Administrative Officer, General Counsel and Corporate Secretary